Rights and permissions
About this article
Cite this article
Ranibizumab not recommended for DMO by NICE. Pharmacoecon. Outcomes News 624, 10 (2011). https://doi.org/10.2165/00151234-201106240-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106240-00025